KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Return on Equity (2016 - 2025)

Historic Return on Equity for Neogenomics (NEO) over the last 16 years, with Q3 2025 value amounting to 0.13%.

  • Neogenomics' Return on Equity fell 500.0% to 0.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.13%, marking a year-over-year decrease of 500.0%. This contributed to the annual value of 0.09% for FY2024, which is 100.0% up from last year.
  • Latest data reveals that Neogenomics reported Return on Equity of 0.13% as of Q3 2025, which was down 500.0% from 0.12% recorded in Q2 2025.
  • Over the past 5 years, Neogenomics' Return on Equity peaked at 0.07% during Q2 2021, and registered a low of 0.16% during Q3 2022.
  • In the last 5 years, Neogenomics' Return on Equity had a median value of 0.09% in 2024 and averaged 0.08%.
  • Per our database at Business Quant, Neogenomics' Return on Equity skyrocketed by 800bps in 2021 and then crashed by -2100bps in 2022.
  • Neogenomics' Return on Equity (Quarter) stood at 0.01% in 2021, then plummeted by -1829bps to 0.14% in 2022, then soared by 35bps to 0.09% in 2023, then grew by 7bps to 0.09% in 2024, then plummeted by -54bps to 0.13% in 2025.
  • Its Return on Equity was 0.13% in Q3 2025, compared to 0.12% in Q2 2025 and 0.09% in Q1 2025.